



## Final Appraisal Recommendation

Advice No: 0712 – March 2012

### Esomeprazole (Nexium® IV) 40 mg powder for solution for injection/infusion

Limited submission by AstraZeneca UK Ltd

#### Recommendation of AWMSG

Esomeprazole (Nexium® IV) is recommended as an option for use within NHS Wales for gastric antisecretory treatment when the oral route is not possible, such as gastro-oesophageal reflux disease (GORD) in patients with erosive reflux oesophagitis and/or severe symptoms of reflux for children and adolescents aged 1–18 years of age.

AWMSG is of the opinion that esomeprazole (Nexium® IV) is suitable for specialist only prescribing within NHS Wales for the above indication.

#### Additional notes:

Esomeprazole (Nexium® IV) for the above indication met the following criteria for a limited submission:

- A minor licence extension.
- Anticipated usage in NHS Wales is considered to be of minimal budgetary impact.
- Estimated small difference in cost compared to the comparator.

In reaching this recommendation AWMSG took account of the AWMSG Secretariat Assessment Report (ASAR), the preliminary appraisal recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion (where available), lay perspective and discussions at AWMSG.

This recommendation has been ratified by Welsh Government and will be considered for review every three years.

Marketing authorisation holder on first issue:	AstraZeneca UK Ltd
Date of first issue	March 2012
Last reviewed	September 2016



NICE has accredited the process used by the All Wales Medicines Strategy Group (AWMSG) to produce its final appraisal recommendation. Accreditation is valid for 5 years from October 2011. More information on accreditation can be viewed at [www.evidence.nhs.uk](http://www.evidence.nhs.uk).

For full details on our accreditation visit: [www.nice.org.uk/accreditation](http://www.nice.org.uk/accreditation).

Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as:

All Wales Medicines Strategy Group. Final Appraisal Recommendation – 0712:  
Esomeprazole (Nexium® IV) 40 mg powder for solution for injection/infusion. March 2012.

